Nelarabine combination therapy for relapsed or refractory T-cell acute lymphoblastic lymphoma/leukemia
Shai Shimony(Twitter (United States)), Marlise R. Luskin(Dana-Farber Cancer Institute), Andrew E. Place(Boston Children's Hospital), Jonathan Paolino(Dana-Farber/Boston Children's Cancer and Blood Disorders Center), Lewis B. Silverman(Columbia University Irving Medical Center), Lachelle D. Weeks(Harvard University), Lynda M. Vrooman(Boston Children's Hospital), Richard M. Stone(Dana-Farber Cancer Institute), Daniel J. DeAngelo(Dana-Farber Cancer Institute), Yannis K. Valtis(Brigham and Women's Hospital), Donna Neuberg(Otsuka (Japan)), Yiwen Liu(University of Arizona), Andrew M. Brunner(Harvard University)
Cited by 40
Related Papers
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k
Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma
|Nature Medicine|2020|1k
United States Multicenter Study of Arsenic Trioxide in Relapsed Acute Promyelocytic Leukemia
|Journal of Clinical Oncology|2001|825